研究
2017 研究業績・論文発表
論文
M. Chiba, Y. Togashi, E. Bannno, Y. Kobayashi, Y. Nakamura, H. Hayashi, M. Terashima, M. A. De Velasco, K. Sakai, Y. Fujita, T. Mitsudomi and K. Nishio
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
BMC Cancer (2017) 17: 281.
Y. Kobayashi, K. Azuma, H. Nagai, Y. H. Kim, Y. Togashi, Y. Sesumi, M. Chiba, M. Shimoji, K. Sato, K. Tomizawa, T. Takemoto, K. Nishio and T. Mitsudomi
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Mol Cancer Ther (2017) 16: 357-364.
T. Mitsudomi
Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation
Lancet Respir Med (2017) 5: 369-370.
Y. Sesumi, K. Suda, H. Mizuuchi, Y. Kobayashi, K. Sato, M. Chiba, M. Shimoji, K. Tomizawa, T. Takemoto and T. Mitsudomi
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Lung Cancer (2017) 104: 85-90.
K. Suda, P. A. Bunn, Jr., C. J. Rivard, T. Mitsudomi and F. R. Hirsch
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
J Thorac Oncol (2017) 12: 27-35.
K. Suda, I. Murakami, H. Yu, J. Kim, K. Ellison, C. J. Rivard, T. Mitsudomi and F. R. Hirsch
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
J Thorac Oncol (2017) 12: 1015-1020.
K. Suda, C. J. Rivard, T. Mitsudomi and F. R. Hirsch
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Expert Rev Anticancer Ther (2017) 17: 779-786.
K. Suda, L. Rozeboom, K. Furugaki, H. Yu, M. A. C. Melnick, K. Ellison, C. J. Rivard, K. Politi, T. Mitsudomi and F. R. Hirsch
Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
Biomed Res Int (2017) 2017: 7694202.
K. Suda, L. Rozeboom, C. J. Rivard, H. Yu, K. Ellison, M. A. C. Melnick, T. K. Hinz, D. Chan, L. E. Heasley, K. Politi, T. Mitsudomi and F. R. Hirsch
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
Lung Cancer (2017) 109: 1-8.
K. Suda, L. Rozeboom, H. Yu, K. Ellison, C. J. Rivard, T. Mitsudomi and F. R. Hirsch
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
PLoS One (2017) 12: e0172209.
K. Tomizawa, S. Shimizu, S. Ohara, T. Fujino, M. Nishino, Y. Sesumi, Y. Kobayashi, K. Sato, M. Chiba, M. Shimoji, K. Suda, T. Takemoto and T. Mitsudomi
Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer
Lung Cancer (2017) 112: 57-61.